The Oncologist,
Clinical Trial Results: Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect…
Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
Overview of attention for article published in Oncologist, March 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (81st percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 76 Mendeley